💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Levomilnacipran Hydrochloride

CHEMBL2105732 Phase 4 Одобрено Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
282.8 g/mol
LogP
—
Phase
4

A hydrochloride salt form of levomilnacipran with the same therapeutic properties. An SNRI antidepressant with strong norepinephrine reuptake inhibition for major depressive disorder.

Молекулярная масса

282,8100 g/mol

TPSA

46,30 Ų

Терапевтические области

Pain Management Major Depressive Disorder Chronic Pain

Механизм действия

Inhibits the reuptake of both serotonin and norepinephrine by blocking their respective presynaptic transporters. This dual mechanism enhances monoaminergic neurotransmission and produces antidepressant and analgesic effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Inhibits the reuptake of both serotonin and norepinephrine by blocking their respective presynaptic transporters. This dual mechanism enhances monoaminergic neurotransmission and produces antidepressant and analgesic effects.

2D Структура

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCN(CC)C(=O)[C@@]1(c2ccccc2)C[C@H]1CN.Cl

                

                

                
                

                    
InChI

                    
InChI=1S/C15H22N2O.ClH/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12;/h5-9,13H,3-4,10-11,16H2,1-2H3;1H/t13-,15+;/m0./s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C15H23ClN2O

                    

                    
                    

                        
HBD / HBA

                        
2 / 2

                    

                    
                    

                        
Вращаемые Связи

                        
5

                    

                    
                    
                    

                        
Тяжёлые Атомы

                        
19

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Часто задаваемые вопросы

                

                    
                    

                        
                        

                            
A hydrochloride salt form of levomilnacipran with the same therapeutic properties. An SNRI antidepressant with strong norepinephrine reuptake inhibition for major depressive disorder.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits the reuptake of both serotonin and norepinephrine by blocking their respective presynaptic transporters. This dual mechanism enhances monoaminergic neurotransmission and produces antidepressant and analgesic effects.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Levomilnacipran Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2105732.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 6917778.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Медицинский отказ от ответственности

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.